CREATE Medicines is a clinical-stage biotechnology company pioneering a new class of in vivo immune programming therapies that directly reprogram immune cells inside the body using a proprietary mRNA-LNP platform. By enabling scalable, redosable, off-the-shelf CAR (chimeric antigen receptor) therapies across multiple immune cell types — including T cells, NK cells, and myeloid cells — CREATE is advancing differentiated treatments for cancer, autoimmunity, and fibrosis. The company has generated human clinical validation, with first-in-human evidence of tolerable repeat dosing, immune activation, and tumor engagement, positioning it at the forefront of transforming immunotherapy with next-generation RNA-based medicines.